P: +1 917-388-1578
A recent report from three COVID-19-designated hospitals in Wuhan, China indicated that more than one-third of coronavirus patients had some type of neurologic symptom, including altered consciousness, evidence of skeletal muscle damage, and acute cerebrovascular disease (access report here). Early data implies that COVID-19, like prior coronavirus breakouts MERS and SARS, is demonstrating a neurologic component in severe cases.
Neurologists and other medical practitioners are urged to follow sanitary techniques to avoid spreading COVID-19 through cross-contamination.
NeuroCap™ is a FDA-cleared disposable EEG headset with 22 electrodes and 19 active EEG channels for performing high quality routine EEG tests.
Its one-use life span minimizes cross-contamination and optimizes sanitary practice. The diagnostic tool can be administered by clinical staff of any level, and it can be used in healthcare facilities or outpatient settings.
NeuroCap™ can stay on patient’s head for up to 4 hours
Takes less that 5 minutes to set up the headset.
Compatible with 3rd party amplifiers via the cable adapter.
Safe, comfortable, and sanitary, with no cleaning or scrubbing required.
The pre-gelled fixed electrode placement eliminates the time-consuming task of placing electrodes and measuring the patient’s head. This enables the use of this device by frontline healthcare workers (nurses, medical assistants) not just specialized EEG technicians.
Can be used anywhere in healthcare facilities.
Available in Small, Medium, and Large sizes.
NeuroCap™ works in parallel with the NeuroEEG™ amplifier, a compact, portable and affordable 16-channel EEG device that fits in the palm of your hand and provides the same quality as traditional bulky EEG equipment.
NeuroEEG can be easily deployed in any medical facility, including emergency departments and testing centers.
FOR NEUROEEG, RENTAL OPTION AVAILABLE.
Safe Harbor: Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this presentation that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements.